- CytRx (CYTR) announces the dosing of the first patient in a Phase 2 study of aldoxorubicin in unresectable GBM.
- Preliminary results expected in H2.
- The company says that if the results are positive, CYTR "will pursue the rapid development of aldoxorubicin for unresectable GBM, including filing for breakthrough therapy designation." (PR)
- CYTR +5% premarket.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs